GZMA and Alzheimer disease: Notably, cysteine’s interaction with GZMA suggests novel AD treatment strategies, presenting a breakthrough in integrating traditional therapies with molecular medicine to potentially improve POP management in AD, promising for both early diagnosis and targeted treatment.